Background: The combination of non-invasive markers for the detection of fibrosis in patients with chronic liver diseases is still a matter of debate. Aims: To test the performance of cytokeratin18-Aspartate396 alone or in combination with transient elastography as a marker of fibrosis, compared to liver biopsy as gold standard. Methods: In 259 prospectively enrolled patients with chronic liver diseases, clinical, biochemical, and histological features were assessed. Serum cytokeratin18-Aspartate396 and Fibroscan were performed within 6 months prior to liver biopsy. Results: Cytokeratin18-Aspartate396 levels predicted both significant and advanced fibrosis in nonalcoholic fatty liver disease group, correctly identifying 83.7% and 80.8% of cases, respectively. Liver stiffness performed best in predicting severe fibrosis in patients with chronic viral infection, correctly identifying 78.7% of chronic hepatitis B and 88.6% of chronic hepatitis C subjects. The combination of cytokeratin18-Aspartate396 and liver stiffness improved their diagnostic performance for the detection of significant and advanced fibrosis in non-alcoholic fatty liver disease group, only (sensitivity = 78.3%, specificity = 90.7%; sensitivity = 91.7%, specificity = 71.6%, respectively). Conclusion: Cytokeratin18-Aspartate396 and liver stiffness can improve the non-invasive prediction of significant and advanced fibrosis in patients with non-alcoholic fatty liver disease, while in hepatitis B and C virus infected patients their combined use had no advantage over the diagnostic accuracy of transient elastography alone.

Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis

ROSSO, CHIARA;CAVIGLIA, GIAN PAOLO;ABATE, Maria Lorena;VANNI, Ester;MEZZABOTTA, Lavinia;OLIVERO, Antonella;MARENGO, Andrea;RIZZETTO, Mario;BUGIANESI, Elisabetta;SMEDILE, Antonina
2016

Abstract

Background: The combination of non-invasive markers for the detection of fibrosis in patients with chronic liver diseases is still a matter of debate. Aims: To test the performance of cytokeratin18-Aspartate396 alone or in combination with transient elastography as a marker of fibrosis, compared to liver biopsy as gold standard. Methods: In 259 prospectively enrolled patients with chronic liver diseases, clinical, biochemical, and histological features were assessed. Serum cytokeratin18-Aspartate396 and Fibroscan were performed within 6 months prior to liver biopsy. Results: Cytokeratin18-Aspartate396 levels predicted both significant and advanced fibrosis in nonalcoholic fatty liver disease group, correctly identifying 83.7% and 80.8% of cases, respectively. Liver stiffness performed best in predicting severe fibrosis in patients with chronic viral infection, correctly identifying 78.7% of chronic hepatitis B and 88.6% of chronic hepatitis C subjects. The combination of cytokeratin18-Aspartate396 and liver stiffness improved their diagnostic performance for the detection of significant and advanced fibrosis in non-alcoholic fatty liver disease group, only (sensitivity = 78.3%, specificity = 90.7%; sensitivity = 91.7%, specificity = 71.6%, respectively). Conclusion: Cytokeratin18-Aspartate396 and liver stiffness can improve the non-invasive prediction of significant and advanced fibrosis in patients with non-alcoholic fatty liver disease, while in hepatitis B and C virus infected patients their combined use had no advantage over the diagnostic accuracy of transient elastography alone.
48
1
55
61
http://www.elsevier.com/wps/find/journalbibliographicinfo.cws_home/623449/description#bibliographicinfo
Chronic liver disease; Cytokeratin 18-Asp396; Liver stiffness; Gastroenterology; Hepatology
Rosso, Chiara; Caviglia, Gian Paolo; Abate, Maria Lorena; Vanni, Ester; Mezzabotta, Lavinia; Touscoz, Giovanni Antonio; Olivero, Antonella; Marengo, Andrea; Rizzetto, Mario; Bugianesi, Elisabetta; Smedile, Antonina
File in questo prodotto:
File Dimensione Formato  
CK 18 DLD 2016.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 580.52 kB
Formato Adobe PDF
580.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1550426
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
social impact